Evidence map›Paper›PMID 38214234›Full record

ArticleNucleic acids research2024

Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors.

Giulia Giacomini, Sandra Piquet, Odile Chevallier, Juliette Dabin, Siau-Kun Bai, Byungjin Kim, Robert Siddaway, Brian Raught, Etienne Coyaud, Chun-Min Shan and 18 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. IncRNA-ZFAS1, an Emerging Gate-Keeper in DNA Damage-Dependent Transcriptional Regulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 8 institutions in 4 countries.

Giulia GiacominiEpigenetics & Cell Fate Centre, CNRS/Université Paris Cité, Paris, France.
Sandra PiquetEpigenetics & Cell Fate Centre, CNRS/Université Paris Cité, Paris, France.
Odile ChevallierEpigenetics & Cell Fate Centre, CNRS/Université Paris Cité, Paris, France.
Juliette DabinEpigenetics & Cell Fate Centre, CNRS/Université Paris Cité, Paris, France.
Siau-Kun BaiEpigenetics & Cell Fate Centre, CNRS/Université Paris Cité, Paris, France.
Byungjin KimArthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada.
Robert SiddawayArthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada.
Brian RaughtPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, ON M5G1L7, Canada.
Etienne CoyaudPrincess Margaret Cancer Centre, University Health Network, 101 College Street, Toronto, ON M5G1L7, Canada.
Chun-Min ShanDepartment of Biological Sciences, Columbia University, New York, NY 10027, USA.ORCID 0000-0002-7080-5221
Robert J D ReidDepartment of Genetics & Development, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-7424-3537
Takenori TodaDepartment of Biological Sciences, Columbia University, New York, NY 10027, USA.
Rodney RothsteinDepartment of Genetics & Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Viviana BarraCNRS UMR9019 Genome Integrity and Cancers, Université Paris-Saclay, Gustave Roussy Institute, Villejuif, France.
Therese WilhelmCNRS UMR9019 Genome Integrity and Cancers, Université Paris-Saclay, Gustave Roussy Institute, Villejuif, France.
Sabah HamadatCNRS UMR9019 Genome Integrity and Cancers, Université Paris-Saclay, Gustave Roussy Institute, Villejuif, France.
Chloé BertinCNRS UMR9019 Genome Integrity and Cancers, Université Paris-Saclay, Gustave Roussy Institute, Villejuif, France.
Alexander CraneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
Frank DuboisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
Ignasi ForneProtein Analysis Unit, BioMedical Center, Faculty of Medicine, Ludwig-Maximilians-University, Martinsried, Germany.ORCID 0000-0003-0309-907X
Axel ImhofProtein Analysis Unit, BioMedical Center, Faculty of Medicine, Ludwig-Maximilians-University, Martinsried, Germany.
Pratiti BandopadhayayDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, USA.
Rameen BeroukhimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
Valeria NaimCNRS UMR9019 Genome Integrity and Cancers, Université Paris-Saclay, Gustave Roussy Institute, Villejuif, France.ORCID 0000-0002-2149-8712
Songtao JiaDepartment of Biological Sciences, Columbia University, New York, NY 10027, USA.ORCID 0000-0002-7927-0227
Cynthia HawkinsArthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada.ORCID 0000-0003-2618-4402
Beatrice RondinelliEpigenetics & Cell Fate Centre, CNRS/Université Paris Cité, Paris, France.
Sophie E PoloEpigenetics & Cell Fate Centre, CNRS/Université Paris Cité, Paris, France.ORCID 0000-0003-4821-9354
Centre National de la Recherche Scientifique · FRBoston University · USColumbia University · USHospital for Sick Children · CACenter for Integrated Protein Science Munich · DEColumbia University Irving Medical Center · USUniversity Health Network · CADana-Farber/Boston Children's Cancer and Blood Disorders Center · US

Funding

Molecular Mechanisms Underlying Recombination at DNA Double-Strand Breaks and Stalled Replication ForksR35GM118180 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Rodney J. ROTHSTEIN · 2016 to 2026
$8.5M
Genetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9M
Mechanism of heterochromatin assembly and oncogenic histone mutationsR35GM126910 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Songtao Jia · 2018 to 2026
$3.8M
CIHR PJT-156407European Research Council ERC-2014-StG-638898NCI NIH HHS R01 CA188228NIGMS NIH HHS R35 GM118180NIGMS NIH HHS R35 GM126910NIH HHS R35GM118180
6 · The paper itself

Abstract

Pediatric high-grade gliomas (pHGG) are devastating and incurable brain tumors with recurrent mutations in histone H3.3. These mutations promote oncogenesis by dysregulating gene expression through alterations of histone modifications. We identify aberrant DNA repair as an independent mechanism, which fosters genome instability in H3.3 mutant pHGG, and opens new therapeutic options. The two most frequent H3.3 mutations in pHGG, K27M and G34R, drive aberrant repair of replication-associated damage by non-homologous end joining (NHEJ). Aberrant NHEJ is mediated by the DNA repair enzyme polynucleotide kinase 3'-phosphatase (PNKP), which shows increased association with mutant H3.3 at damaged replication forks. PNKP sustains the proliferation of cells bearing H3.3 mutations, thus conferring a molecular vulnerability, specific to mutant cells, with potential for therapeutic targeting.

Indexed as

Brain NeoplasmsGliomaHistonesChildDNA RepairDNA Repair EnzymesHumansMutationPhosphotransferases (Alcohol Group Acceptor)DNA Repair EnzymesHistonesPhosphotransferases (Alcohol Group Acceptor)PNKP protein, human

Identifiers

PMID38214234
PMCPMC10954481
OpenAlexW4390790975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.